Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Masimo Pronto-7 wins Japanese, Canadian approval

Masimo, a developer of noninvasive monitoring technologies, has received approval from the Japanese Ministry of Health Labor & Welfare (MHLW) and Health Canada for its Pronto-7.

Pronto-7 is a palm-sized, handheld device which aids clinicians to noninvasively measure total hemoglobin (SpHb), SpO2, perfusion index, and pulse rate in less than one minute.

Masimo SpHb provides immediate real-time hemoglobin results and facilitates clinicians to assess patients and detect and treat internal bleeding and low hemoglobin conditions earlier.

In addition to Normal Mode, Pronto-7 offers Max Sensitivity Mode that allows measurement over a broader range of patients and three noninvasive sensor sizes to accommodate the range of finger diameters.

Each sensor is color-coded to make size identification easy (Small-Yellow, Medium-Red, and Large-White) and optimized to improve performance in low ambient temperatures.

Masimo founder and CEO Joe Kiani said they believe that the Pronto-7 will help clinicians to better assess more patients and make better clinical decisions based on the availability of quick and noninvasive hemoglobin measurement.

Masimo Pronto-7 is pending FDA 510(k) clearance in the US.